WS
WST
—
NYSE
Diversified Medical Equipment & Supplies
West Pharmaceutical Services Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
25,2B USD
P/E
51,5x
EV / Rev
8,2x
Div yield
0,24 %
Op margin
19,0 %
ROE
16,5 %
Net margin
16,1 %
Debt / equity
0,07
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$355,48
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
WEST PHARMACEUTICAL SERVICES INC is classified under Energy / Oil & Gas Exploration & Production and appears profitable on the latest normalized snapshot.
Business. West Pharmaceutical Services Inc (NYSE: WST) is a company classified within the Oil & Gas Exploration & Production industry. The firm operates primarily through a product-sale revenue model. Specific details regarding its operating segments and geographic mix are not available. The company is headquartered in the United States and is listed on the New York Stock Exchange.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · rules-based
Sell-side consensus
BUY19 analysts
18 buy1 hold0 sell
Avg 12m price target389,54
Analyst recommendations
19 analysts · consensus BuyBuy18
Hold1
Sell0
12-month price target
389,54
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation→
51,5x
P/E
Analysts→
Buy
19 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
16,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to WST. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressLisa McClain — West Pharmaceutical Services, Inc.2025-07-22 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — West Pharmaceutical Services, Inc.2025-06-17 · Republican · MI · Purchase · $1,001 - $15,000
- CongressJared Moskowitz — West Pharmaceutical Services, Inc.2025-02-13 · Democrat · FL · Sale · $1,001 - $15,000
- CongressJared Moskowitz — West Pharmaceutical Services, Inc.2023-12-28 · Democrat · FL · Purchase · $1,001 - $15,000
Pre-earnings brief
Briefing · model-assisted
West Pharmaceutical Services Inc (WST) has entered the system for its first analysis, establishing a baseline with no prior data available for computing material changes or deltas. This initial snapshot provides the foundational context for monitoring the company's financial and operational metrics moving forward. The most significant activity detected involves major modifications to institutional holdings reported as of March 31, 2026. Specifically, investor ID 931 adjusted its position from 25 shares to 26,221 shares, representing a value of approximately $6.38 million and a portfolio weight of 0.003%. Concurrently, investor ID 587 increased its stake from 1,552 shares to 25,856 shares, valued at roughly $6.48 million with a weight of 0.0037%. These adjustments were detected in late June and early July 2026, indicating a notable shift in ownership concentration during this period. These holder changes are the primary signals available, as no cross-source signals or analyst estimates were recorded in the current dataset. The absence of analyst coverage and officer count data in the initial profile suggests that the focus remains strictly on the reported equity positions and their immediate impact on the shareholder structure. For investors, these substantial increases in share counts by specific institutional holders highlight a growing interest or strategic accumulation in WST during the first quarter of 2026. With 37 top holders identified and membership in one index, the company maintains a structured ownership base, but the recent major modifications underscore the dynamic nature of its institutional support. Monitoring these positions will be critical for understanding future liquidity and governance implications.
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
West Pharmaceutical Services Inc (NYSE: WST) is a company classified within the Oil & Gas Exploration & Production industry. The firm operates primarily through a product-sale revenue model. Specific details regarding its operating segments and geographic mix are not available. The company is headquartered in the United States and is listed on the New York Stock Exchange.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
AI synthesis
GENERATEDWEST PHARMACEUTICAL SERVICES INC (WST) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.77 (rule-based classification). Capital structure on the latest snapshot: total assets 4,109,800,000 USD, total equity 2,990,400,000, short-term debt 0, long-term debt 202,800,000. Net cash position is approximately 318,600,000 USD. Self-calculated market cap is 25,449,686,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 844,900,000, gross profit 296,400,000, operating income 177,100,000, net income 138,800,000. Return on equity ~16.5%. Return on assets ~12.0%. Operating-cash-flow to net-income ratio is 1.53. Risk profile from automated assessment: liquidity risk low, dilution risk medium. Flags: Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on WST — filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0000105770-26-000097). Additional context: 8-K: filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material.
West Pharmaceutical Services Inc (WST) has entered the system for its first analysis, establishing a baseline with no prior data available for computing material changes or deltas. This initial snapshot provides the foundational context for monitoring the company's financial and operational metrics moving forward. The most significant activity detected involves major modifications to institutional holdings reported as of March 31, 2026. Specifically, investor ID 931 adjusted its position from 25 shares to 26,221 shares, representing a value of approximately $6.38 million and a portfolio weight of 0.003%. Concurrently, investor ID 587 increased its stake from 1,552 shares to 25,856 shares, valued at roughly $6.48 million with a weight of 0.0037%. These adjustments were detected in late June and early July 2026, indicating a notable shift in ownership concentration during this period. These holder changes are the primary signals available, as no cross-source signals or analyst estimates were recorded in the current dataset. The absence of analyst coverage and officer count data in the initial profile suggests that the focus remains strictly on the reported equity positions and their immediate impact on the shareholder structure. For investors, these substantial increases in share counts by specific institutional holders highlight a growing interest or strategic accumulation in WST during the first quarter of 2026. With 37 top holders identified and membership in one index, the company maintains a structured ownership base, but the recent major modifications underscore the dynamic nature of its institutional support. Monitoring these positions will be critical for understanding future liquidity and governance implications.
Key takeaways
- Observed GAAP P/E is about 51.55x.
- Return on equity is about 16.5%.
- Debt to equity is about 0.07x.
- [TRIGGER] 8-K: 8-K (sec_8k_material) on WST — filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0000105770-26-000097)
- wst-20260331 0000105770 --12-31 2026 Q1 false http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent P24M P12M 15 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:segment wst:program 0000105770 2026-01-01 2026-03-31 0000105770 2026-04-20 0000105770 2025-01-01 2025-03-31 0000105770 2026-03-31 0000105770 2025-12-31 0000105770 2024-12-31 0000105770 2025-03-31 0000105770 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember wst:SmartDose3.5mLOnBodyDeliverySystemAndAssociatedFacilitiesMember 2025-12-31 0000105770 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember wst:SmartDose3.5mLOnBodyDeliverySystemAndAssociatedFacilitiesMember 2026-03-31 0000105770 wst:BiologicsCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:BiologicsCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:GenericsCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:GenericsCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:PharmaCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:PharmaCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:WestVantageCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:WestVantageCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:HighValueComponentsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:HighValueComponentsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:HighValueDeliveryDevicesMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:HighValueDeliveryDevicesMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:StandardPackagingMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:StandardPackagingMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 wst:WestVantageProductAndServiceMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 wst:WestVantageProductAndServiceMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 srt:AmericasMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 srt:AmericasMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 us-gaap:EMEAMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 us-gaap:EMEAMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 srt:AsiaPacificMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 srt:AsiaPacificMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0000105770 us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0000105770 2027-04-01 2026-03-31 0000105770 2026-04-01 2026-03-31 0000105770 2023-02-28 0000105770 2026-02-28 0000105770 srt:AffiliatedEntityMember 2026-03-31 0000105770 srt:AffiliatedEntityMember 2025-12-31 0000105770 srt:AffiliatedEntityMember 2026-01-01 2026-03-31 0000105770 srt:AffiliatedEntityMember 2025-01-01 2025-03-31 0000105770 wst:TermLoanDue2027Member 2026-03-31 0000105770 wst:TermLoanDue2027Member 2025-12-31 0000105770 wst:SeniorCNotesDue2027Member 2026-03-31 0000105770 wst:SeniorCNotesDue2027Member 2025-12-31 0000105770 wst:TermLoansMember 2026-03-31 0000105770 us-gaap:RevolvingCreditFacilityMember wst:Revolvingcreditfacilitydue2024Member 2026-03-31 0000105770 us-gaap:LetterOfCreditMember wst:Revolvingcreditfacilitydue2024Member 2026-03-31 0000105770 us-gaap:ForwardContractsMember wst:IntercompanyLoansMember currency:SGD 2026-03-31 0000105770 us-gaap:ForwardContractsMember wst:IntercompanyLoansMember currency:SGD 2025-12-31 0000105770 us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember currency:EUR 2026-03-31 0000105770 us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember currency:EUR 2025-12-31 0000105770 us-gaap:ForeignExchangeForwardMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:EUR us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:EUR us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:JPY us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:JPY us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:SGD us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2026-03-31 0000105770 us-gaap:ForeignExchangeForwardMember currency:SGD us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2026-03-31 0000105770 us-gaap:CrossCurrencyInterestRateContractMember currency:USD us-gaap:NetInvestmentHedgingMember 2024-07-31 0000105770 us-gaap:CrossCurrencyInterestRateContractMember currency:JPY us-gaap:NetInvestmentHedgingMember 2026-03-31 0000105770 us-gaap:CrossCurrencyInterestRateContractMember currency:USD us-gaap:NetInvestmentHedgingMember 2026-03-31 0000105770 us-gaap:OptionMember 2026-01-01 2026-03-31 0000105770 us-gaap:OptionMember 2026-03-31 0000105770 wst:OtherExpenseIncomeMember 2026-01-01 2026-03-31 0000105770 wst:OtherExpenseIncomeMember 2025-01-01 2025-03-31 0000105770 us-gaap:FairValueHedgingMember 2026-01-01 2026-03-31 0000105770 us-gaap:FairValueHedgingMember 2025-01-01 2025-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2025-01-01 2025-03-31 0000105770 us-gaap:ForeignExchangeContractMember wst:NetSalesMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForeignExchangeContractMember wst:NetSalesMember 2025-01-01 2025-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0000105770 us-gaap:CurrencySwapMember 2026-01-01 2026-03-31 0000105770 us-gaap:CurrencySwapMember 2025-01-01 2025-03-31 0000105770 wst:NetSalesMember 2026-01-01 2026-03-31 0000105770 wst:NetSalesMember 2025-01-01 2025-03-31 0000105770 us-gaap:CostOfSalesMember 2026-01-01 2026-03-31 0000105770 us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0000105770 us-gaap:InterestExpenseMember 2026-01-01 2026-03-31 0000105770 us-gaap:InterestExpenseMember 2025-01-01 2025-03-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember wst:OtherExpenseIncomeMember 2026-01-01 2026-03-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember wst:OtherExpenseIncomeMember 2025-01-01 2025-03-31 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember wst:OtherExpenseIncomeMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember wst:OtherExpenseIncomeMember 2025-01-01 2025-03-31 0000105770 us-gaap:NondesignatedMember 2026-01-01 2026-03-31 0000105770 us-gaap:NondesignatedMember 2025-01-01 2025-03-31 0000105770 us-gaap:FairValueInputsLevel1Member 2026-03-31 0000105770 us-gaap:FairValueInputsLevel2Member 2026-03-31 0000105770 us-gaap:FairValueInputsLevel3Member 2026-03-31 0000105770 us-gaap:MoneyMarketFundsMember 2026-03-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0000105770 us-gaap:BankTimeDepositsMember 2026-03-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0000105770 us-gaap:CurrencySwapMember 2026-03-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0000105770 us-gaap:CommodityMember 2026-03-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0000105770 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000105770 us-gaap:MoneyMarketFundsMember 2025-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000105770 us-gaap:BankTimeDepositsMember 2025-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000105770 us-gaap:CurrencySwapMember 2025-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000105770 us-gaap:CommodityMember 2025-12-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000105770 us-gaap:CommodityMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2025-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2026-01-01 2026-03-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2026-01-01 2026-03-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2026-01-01 2026-03-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-03-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2026-03-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2026-03-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2026-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2024-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2025-01-01 2025-03-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-03-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2025-03-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2026-01-01 2026-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000105770 us-gaap:CommonStockMember 2025-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2025-12-31 0000105770 us-gaap:RetainedEarningsMember 2025-12-31 0000105770 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0000105770 us-gaap:CommonStockMember 2026-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2026-03-31 0000105770 us-gaap:RetainedEarningsMember 2026-03-31 0000105770 us-gaap:CommonStockMember 2024-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2024-12-31 0000105770 us-gaap:RetainedEarningsMember 2024-12-31 0000105770 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000105770 us-gaap:CommonStockMember 2025-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2025-03-31 0000105770 us-gaap:RetainedEarningsMember 2025-03-31 0000105770 2025-05-01 2025-05-31 0000105770 wst:ShareBasedPaymentArrangementOptionAndStockAppreciationRightsMember 2025-05-01 2025-05-31 0000105770 wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember 2025-05-01 2025-05-31 0000105770 wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember 2025-02-28 2025-02-28 0000105770 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0000105770 srt:MinimumMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0000105770 srt:MaximumMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0000105770 srt:MinimumMember 2025-01-01 2025-01-31 0000105770 srt:MaximumMember 2025-01-01 2025-01-31 0000105770 srt:MinimumMember 2025-01-31 0000105770 srt:MaximumMember 2025-01-31 0000105770 us-gaap:EmployeeSeveranceMember wst:January2025RestructuringPlanMember 2025-12-31 0000105770 wst:AssetRelatedChargesMember wst:January2025RestructuringPlanMember 2025-12-31 0000105770 wst:January2025RestructuringPlanMember 2025-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:January2025RestructuringPlanMember 2026-01-01 2026-03-31 0000105770 wst:AssetRelatedChargesMember wst:January2025RestructuringPlanMember 2026-01-01 2026-03-31 0000105770 wst:January2025RestructuringPlanMember 2026-01-01 2026-03-31 0000105770 us-gaap:EmployeeSeveranceMember wst:January2025RestructuringPlanMember 2026-03-31 0000105770 wst:AssetRelatedChargesMember wst:January2025RestructuringPlanMember 2026-03-31 0000105770 wst:January2025RestructuringPlanMember 2026-03-31 0000105770 srt:MinimumMember 2025-12-01 2025-12-31 0000105770 srt:MaximumMember 2025-12-01 2025-12-31 0000105770 srt:MinimumMember 2025-12-31 0000105770 srt:MaximumMember 2025-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:December2025RestructuringPlanMember 2025-12-31 0000105770 wst:December2025RestructuringPlanMember 2025-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:December2025RestructuringPlanMember 2026-01-01 2026-03-31 0000105770 wst:December2025RestructuringPlanMember 2026-01-01 2026-03-31 0000105770 us-gaap:EmployeeSeveranceMember wst:December2025RestructuringPlanMember 2026-03-31 0000105770 wst:December2025RestructuringPlanMember 2026-03-31 0000105770 wst:ProprietaryProductsMember 2026-01-01 2026-03-31 0000105770 wst:ProprietaryProductsMember 2025-01-01 2025-03-31 0000105770 wst:WestVantageSegmentMember 2026-01-01 2026-03-31 0000105770 wst:WestVantageSegmentMember 2025-01-01 2025-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2026-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2025-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:WestVantageSegmentMember 2026-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:WestVantageSegmentMember 2025-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2026-03-31 0000105770 wst:CorporateAndReconcilingItemsMember 2025-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2026-01-01 2026-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2025-01-01 2025-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:WestVantageSegmentMember 2026-01-01 2026-03-31 0000105770 us-gaap:OperatingSegmentsMember wst:WestVantageSegmentMember 2025-01-01 2025-03-31 0000105770 wst:CorporateAndReconcilingItemsMember 2026-01-01 2026-03-31 0000105770 wst:CorporateAndReconcilingItemsMember 2025-01-01 2025-03-31 0000105770 us-gaap:OperatingSegmentsMember 2026-01-01 2026-03-31 0000105770 us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0000105770 wst:CorporateAndReconcilingItemsMember wst:OtherIncomeExpenseMember 2026-01-01 2026-03-31 0000105770 wst:CorporateAndReconcilingItemsMember wst:OtherIncomeExpenseMember 2025-01-01 2025-03-31 0000105770 wst:CorporateAndReconcilingItemsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-31 0000105770 wst:CorporateAndReconcilingItemsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0000105770 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember wst:SmartDose3.5mLOnBodyDeliverySystemAndAssociatedFacilitiesMember 2026-01-01 2026-03-31 0000105770 wst:EricMGreenMember 2026-01-01 2026-03-31 0000105770 wst:EricMGreenMember 2026-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
- and Subsidiaries (in millions) Three Months Ended March 31, 2026 2025 Cash flows from operating activities: Net income $ 138.8 $ 89.8 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 44.6 39.1 Amortization 0.6 0.9 Stock-based compensation 6.6 1.3 Non-cash restructuring charges 0.9 0.8 Asset impairments 0.3 0.3 Other non-cash items, net 1.0 ( 2.9 ) Changes in assets and liabilities ( 102.9 ) 0.1 Net cash provided by operating activities 89.9 129.4 Cash flows from investing activities: Capital expenditures ( 42.7 ) ( 71.3 ) Net cash used in investing activities ( 42.7 ) ( 71.3 ) Cash flows from financing activities: Principal repayments on finance leases ( 0.3 ) ( 0.2 ) Dividend payments ( 15.8 ) ( 15.2 ) Proceeds from stock-based compensation awards 5.5 2.5 Employee stock purchase plan contributions 2.0 1.9 Shares purchased under share repurchase programs ( 297.6 ) ( 133.5 ) Shares repurchased for employee tax withholdings ( 2.5 ) ( 2.5 ) Net cash used in financing activities ( 308.7 ) ( 147.0 ) Effect of exchange rates on cash ( 8.4 ) 8.5 Net decrease in cash and cash equivalents ( 269.9 ) ( 80.4 ) Cash, including cash equivalents at beginning of period 791.3 484.6 Cash, including cash equivalents at end of period $ 521.4 $ 404.2 Supplemental cash flow information: Accrued capital expenditures $ 26.1 $ 37.5 See accompanying notes to condensed consolidated financial statements.
Bull / Bear case
Generated · model-assistedBULL CASE · 2
West Pharmaceutical Services exhibits minimal leverage with a debt-to-equity ratio of 0.06, far below the 0.33 peer median.
The firm generated $469 million in free cash flow for FY2025, supporting strong liquidity and financial flexibility.
BEAR CASE · 2
Operating income fell 2.6% year-over-year, suggesting margin pressure or volume declines impacting core operational performance.
The company faces medium dilution risk, which could negatively impact per-share value for existing equity holders over time.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $844.9M; Operating income $177.1M.
Revenue$844.9M
Operating income$177.1M
Net income$138.8M
Free cash flow$47.2M
EPS—
Operating cash flow$89.9M
Financials
Income statement
Revenue$844.9M
Gross profit$296.4M
Operating income$177.1M
Net income$138.8M
Margins
Gross margin35.1%
Operating margin21.0%
Net margin16.4%
FCF margin5.6%
Balance sheet
Total assets$4.11B
Total liabilities$1.12B
Total equity$2.99B
Cash & equivalents$521.4M
Long-term debt$202.8M
Cash flow
Operating cash flow$89.9M
CapEx$42.7M
Free cash flow$47.2M
SBC$6.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $844.9M
- ▍Operating income $177.1M
- ▍Net margin 16.4%
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Revenue $2.27B; Operating income $428.3M.
Revenue$2.27B
Operating income$428.3M
Net income$361.6M
Free cash flow$293.9M
EPS—
Operating cash flow$503.7M
Financials
Income statement
Revenue$2.27B
Gross profit$800.1M
Operating income$428.3M
Net income$361.6M
Margins
Gross margin35.3%
Operating margin18.9%
Net margin15.9%
FCF margin13.0%
Balance sheet
Total assets$4.11B
Total liabilities$1.05B
Total equity$3.05B
Cash & equivalents$628.5M
Long-term debt$202.7M
Cash flow
Operating cash flow$503.7M
CapEx$209.8M
Free cash flow$293.9M
SBC$17.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.27B
- ▍Operating income $428.3M
- ▍Net margin 15.9%
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Revenue $1.46B; Operating income $260.7M.
Revenue$1.46B
Operating income$260.7M
Net income$221.6M
Free cash flow$160.0M
EPS—
Operating cash flow$306.5M
Financials
Income statement
Revenue$1.46B
Gross profit$505.8M
Operating income$260.7M
Net income$221.6M
Margins
Gross margin34.5%
Operating margin17.8%
Net margin15.1%
FCF margin10.9%
Balance sheet
Total assets$3.95B
Total liabilities$1.02B
Total equity$2.93B
Cash & equivalents$509.7M
Long-term debt$202.6M
Cash flow
Operating cash flow$306.5M
CapEx$146.5M
Free cash flow$160.0M
SBC$8.7M
P&L flow · revenue → net income
Highlights
- ▍Revenue $1.46B
- ▍Operating income $260.7M
- ▍Net margin 15.1%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $3.07B; Operating income $584.9M.
Revenue$3.07B
Operating income$584.9M
Net income$493.7M
Free cash flow$468.9M
EPS—
Operating cash flow$754.8M
Financials
Income statement
Revenue$3.07B
Gross profit$1.10B
Operating income$584.9M
Net income$493.7M
Margins
Gross margin35.9%
Operating margin19.0%
Net margin16.1%
FCF margin15.3%
Balance sheet
Total assets$4.27B
Total liabilities$1.09B
Total equity$3.18B
Cash & equivalents$791.3M
Long-term debt$202.8M
Cash flow
Operating cash flow$754.8M
CapEx$285.9M
Free cash flow$468.9M
SBC$23.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.07B
- ▍Operating income $584.9M
- ▍Net margin 16.1%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $2.89B; Operating income $569.9M.
Revenue$2.89B
Operating income$569.9M
Net income$492.7M
Free cash flow$276.4M
EPS—
Operating cash flow$653.4M
Financials
Income statement
Revenue$2.89B
Gross profit$998.5M
Operating income$569.9M
Net income$492.7M
Margins
Gross margin34.5%
Operating margin19.7%
Net margin17.0%
FCF margin9.6%
Balance sheet
Total assets$3.64B
Total liabilities$961.1M
Total equity$2.68B
Cash & equivalents$484.6M
Long-term debt$202.6M
Cash flow
Operating cash flow$653.4M
CapEx$377.0M
Free cash flow$276.4M
SBC$18.7M
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.89B
- ▍Operating income $569.9M
- ▍Net margin 17.0%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $2.89B; Operating income $569.9M.
Revenue$2.89B
Operating income$569.9M
Net income$492.7M
Free cash flow$276.4M
EPS—
Operating cash flow$653.4M
Financials
Income statement
Revenue$2.89B
Gross profit$998.5M
Operating income$569.9M
Net income$492.7M
Margins
Gross margin34.5%
Operating margin19.7%
Net margin17.0%
FCF margin9.6%
Balance sheet
Total assets$3.64B
Total liabilities$961.1M
Total equity$2.68B
Cash & equivalents$484.6M
Long-term debt$202.6M
Cash flow
Operating cash flow$653.4M
CapEx$377.0M
Free cash flow$276.4M
SBC$18.7M
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.89B
- ▍Operating income $569.9M
- ▍Net margin 17.0%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $2.95B; Operating income $676.0M.
Revenue$2.95B
Operating income$676.0M
Net income$593.4M
Free cash flow$414.5M
EPS—
Operating cash flow$776.5M
Financials
Income statement
Revenue$2.95B
Gross profit$1.13B
Operating income$676.0M
Net income$593.4M
Margins
Gross margin38.3%
Operating margin22.9%
Net margin20.1%
FCF margin14.1%
Balance sheet
Total assets$3.83B
Total liabilities$948.5M
Total equity$2.88B
Cash & equivalents$853.9M
Long-term debt$72.8M
Cash flow
Operating cash flow$776.5M
CapEx$362.0M
Free cash flow$414.5M
SBC$23.3M
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.95B
- ▍Operating income $676.0M
- ▍Net margin 20.1%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $2.95B; Operating income $676.0M.
Revenue$2.95B
Operating income$676.0M
Net income$593.4M
Free cash flow$414.5M
EPS—
Operating cash flow$776.5M
Financials
Income statement
Revenue$2.95B
Gross profit$1.13B
Operating income$676.0M
Net income$593.4M
Margins
Gross margin38.3%
Operating margin22.9%
Net margin20.1%
FCF margin14.1%
Balance sheet
Total assets$3.83B
Total liabilities$948.5M
Total equity$2.88B
Cash & equivalents$853.9M
Long-term debt$72.8M
Cash flow
Operating cash flow$776.5M
CapEx$362.0M
Free cash flow$414.5M
SBC$23.3M
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.95B
- ▍Operating income $676.0M
- ▍Net margin 20.1%
Valuation FY
Market price
$347,94
Market cap
$25.45B
Enterprise valueⓘ
$25.13B
P/Eⓘ
51.5x
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
8.2x
EV / Op incomeⓘ
43.0x
EV / OCFⓘ
33.3x
P / Bⓘ
8.8x
P / Tangible bookⓘ
8.8x
Tangible book
$2.87B
Net cashⓘ
$318.6M
Current ratioⓘ
2.7
Debt / equityⓘ
0.1
ROAⓘ
12.0%
ROEⓘ
16.5%
Cash conversionⓘ
153.0%
CapEx / revenueⓘ
9.3%
SBC / revenueⓘ
0.8%
Dilution ratioⓘ
2.1%
Revenue by segment
Contract Manufacturing—
disclosed · sec_xbrl · 2025-12-31
Drug Delivery Systems & Packaging—
disclosed · sec_xbrl · 2025-12-31
Business relationships
Business relationships40 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries40
EX21:01145366a560EX21:01145366a560Subsidiarie97%
EX21:06700f78c9f7EX21:06700f78c9f7Subsidiarie97%
EX21:08c3f45d8312EX21:08c3f45d8312Subsidiarie97%
EX21:182d5e55a52cEX21:182d5e55a52cSubsidiarie97%
EX21:24b085f9ab66EX21:24b085f9ab66Subsidiarie97%
EX21:294b4596d3b2EX21:294b4596d3b2Subsidiarie97%
EX21:2ce84f424183EX21:2ce84f424183Subsidiarie97%
EX21:2e88b70b69a5EX21:2e88b70b69a5Subsidiarie97%
EX21:4f0dad90454fEX21:4f0dad90454fSubsidiarie97%
EX21:5cd5227a4d78EX21:5cd5227a4d78Subsidiarie97%
EX21:5f2172a1009aEX21:5f2172a1009aSubsidiarie97%
EX21:6379406580bdEX21:6379406580bdSubsidiarie97%
EX21:6879cfce39d3EX21:6879cfce39d3Subsidiarie97%
EX21:76351c8f8ed6EX21:76351c8f8ed6Subsidiarie97%
EX21:7eb69368e2b0EX21:7eb69368e2b0Subsidiarie97%
EX21:802ae9e582c6EX21:802ae9e582c6Subsidiarie97%
EX21:82e1db94f1e5EX21:82e1db94f1e5Subsidiarie97%
EX21:8d8a28b19f9dEX21:8d8a28b19f9dSubsidiarie97%
EX21:90adf6da6289EX21:90adf6da6289Subsidiarie97%
EX21:92d48144bde3EX21:92d48144bde3Subsidiarie97%
EX21:9d7187b70db1EX21:9d7187b70db1Subsidiarie97%
EX21:a066518941e9EX21:a066518941e9Subsidiarie97%
EX21:a1060f553367EX21:a1060f553367Subsidiarie97%
EX21:aeee7533f945EX21:aeee7533f945Subsidiarie97%
EX21:afdba63e3dd9EX21:afdba63e3dd9Subsidiarie97%
EX21:b4b498c6e4a6EX21:b4b498c6e4a6Subsidiarie97%
EX21:b8299a3f87a5EX21:b8299a3f87a5Subsidiarie97%
EX21:bc09fb962894EX21:bc09fb962894Subsidiarie97%
EX21:bf203d4ad3c8EX21:bf203d4ad3c8Subsidiarie97%
EX21:c5701aab316cEX21:c5701aab316cSubsidiarie97%
EX21:ce3dc7efd3d8EX21:ce3dc7efd3d8Subsidiarie97%
EX21:d00c3f482261EX21:d00c3f482261Subsidiarie97%
EX21:d185b5df4527EX21:d185b5df4527Subsidiarie97%
EX21:d27c385bc133EX21:d27c385bc133Subsidiarie97%
EX21:d47470b75876EX21:d47470b75876Subsidiarie97%
EX21:e23b1b04354eEX21:e23b1b04354eSubsidiarie97%
EX21:efb8fbf4e803EX21:efb8fbf4e803Subsidiarie97%
EX21:f246ee2b7b4aEX21:f246ee2b7b4aSubsidiarie97%
EX21:fb442c966964EX21:fb442c966964Subsidiarie97%
EX21:fe071d6bd82cEX21:fe071d6bd82cSubsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Segment revenue · next quarter
No quarterly segment estimate
Segment data is reported at full-fiscal-year granularity only — no quarterly segment split is forecast (a quarterly figure is never inferred from the annual). See the full-fiscal-year segment-revenue card below.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 8,62 |
| Revenue | —no estimate | —no estimate | 3,3B USD |
| Operating income | —no estimate | —no estimate | 724,2M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Segment-revenue forecast · full fiscal year · native currency
- FY2026 — next full year (forecast) · projected off FY2025 close, as of 2025-12-31 · conf —2,6BFORECAST
- FY2026 — next full year (forecast) · projected off FY2025 close, as of 2025-12-31 · conf —597,4MFORECAST
- FY2024 — reported · conf —2,5BREPORTED
- FY2025 — reported · conf —2,4BREPORTED
- FY2025 — reported · conf —573,5MREPORTED
- FY2024 — reported · conf —567,1MREPORTED
Model estimate of reported / forward segment revenue in issuer-native currency. Confidence shown where the model calibrated it; "—" where not (never inferred).
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-31 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution19 analysts
Strong buy5
Buy11
Hold3
Sell0
Strong sell0
12-month price target$346,05 · Median $345,00
Low $309,81High $400,00
Operating income · consensus724,2M USD
EPS surprise
−15,4 %
reported vs consensus · miss
Revenue surprise
−7,6 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$310,22
Mean$389,54
Median$400,00
High$447,00
Spot$347,94
+12.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin19,0 %Above P75
Net Margin16,1 %Above P75
ROE16,5 %Above P75
Capex / Rev9,3 %Best in class
D/E0,07Above median
Cash Conv1,53Above median
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-31 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 42 256 sh8 exercises · 16 grants9 insiders
- Director · Phantom Stock Unit → Common StockAcquired 46grant · 2026-06-30
- SVP, Proprietary Segment · Rst. Stock Unit → Common StockDisposed 474exercise · 2026-05-12
- SVP, Proprietary Segment · Rst. Stock Unit → Common StockDisposed 296exercise · 2026-05-12
- VP, Chief Accounting Officer · Stock Options (Right to Buy) → Common StockDisposed 896 @ $173,22exercise · 2026-04-27
- Sr. VP & Chief HR Officer · Stock Options (Right to Buy) → Common StockDisposed 2 817 @ $83,47exercise · 2026-04-27
- Director · Phantom Stock Unit → Common StockAcquired 52grant · 2026-03-31
- Sr. VP & Chief HR Officer · Rst. Stock Unit → Common StockAcquired 720grant · 2026-03-01
- SVP, Strategy & Corporate Dev · Rst. Stock Unit → Common StockAcquired 437grant · 2026-03-01
- SVP, Strategy & Corporate Dev · Stock Option (Right to Buy) → Common StockAcquired 1 040 @ $254,34grant · 2026-03-01
- VP, Chief Accounting Officer · Rst. Stock Unit → Common StockAcquired 340grant · 2026-03-01
- VP, Chief Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 808 @ $254,34grant · 2026-03-01
- SVP, GC & Corporate Secretary · Rst. Stock Unit → Common StockAcquired 1 285grant · 2026-03-01
- SVP, GC & Corporate Secretary · Stock Option (Right to Buy) → Common StockAcquired 3 057 @ $254,34grant · 2026-03-01
- Director, President, CEO and Board Chair · Rst. Stock Unit → Common StockAcquired 6 986grant · 2026-03-01
- Director, President, CEO and Board Chair · Stock Option (Right to Buy) → Common StockAcquired 16 630 @ $254,34grant · 2026-03-01
- SVP & Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 7 337 @ $254,34grant · 2026-03-01
- Sr. VP & Chief HR Officer · Stock Option (Right to Buy) → Common StockAcquired 1 712 @ $254,34grant · 2026-03-01
- SVP, Proprietary Segment · Rst. Stock Unit → Common StockAcquired 1 131grant · 2026-03-01
- SVP, Proprietary Segment · Stock Option (Right to Buy) → Common StockAcquired 2 691 @ $254,34grant · 2026-03-01
- SVP & Chief Financial Officer · Rst. Stock Unit → Common StockAcquired 3 082grant · 2026-03-01
- VP, Chief Accounting Officer · Rst. Stock Unit → Common StockDisposed 89exercise · 2026-02-20
- VP & Treasurer · Rst. Stock Unit → Common StockDisposed 60exercise · 2026-02-20
- SVP, Strategy & Corporate Dev · Rst. Stock Unit → Common StockDisposed 383exercise · 2026-02-20
- SVP, Strategy & Corporate Dev · Rst. Stock Unit → Common StockDisposed 82exercise · 2026-02-18
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- WEST PHARMACEUTICAL SERVICES INC company facts · 2026-07-26
- WEST PHARMACEUTICAL SERVICES INC 10-Q 2026-04-23 · 2026-07-26
- WEST PHARMACEUTICAL SERVICES INC 10-K 2026-02-17 · 2026-07-26
- WEST PHARMACEUTICAL SERVICES INC 10-Q 2025-10-23 · 2026-07-26
- WEST PHARMACEUTICAL SERVICES INC 10-Q 2025-07-24 · 2026-07-26
- 8-K (sec_8k_material) on WST · 2026-07-26
- West Pharmaceutical Services Inc Market data — analyst estimates · 2026-07-26
- West Pharmaceutical Services Inc Market data — ESG · 2026-07-26
- West Pharmaceutical Services Inc — company reference export (2026-07-05) · 2026-07-26
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,40 %$1M
- Institutional Investor · as of 2026-03-310,11 %$618M
- Investment Managers · as of 2026-03-310,07 %$128M
- Institutional Investor · as of 2022-09-300,07 %$0M
- Investment Managers · as of 2024-12-310,06 %$205M
- Investment Managers · as of 2024-06-300,06 %$2 496M
- Investment Managers · as of 2026-03-310,05 %$100M
- Funds · as of 2026-03-310,04 %$265M
- Investment Managers · as of 2025-12-310,04 %$2 625M
- Investment Managers · as of 2026-03-310,03 %$67M
- Investment Managers · as of 2026-03-310,03 %$478M
- Investment Managers · as of 2026-03-310,03 %$826M
- Investment Managers · as of 2026-03-310,02 %$183M
- Investment Managers · as of 2026-03-310,02 %$116M
- Investment Managers · as of 2026-03-310,02 %$182M
- Investment Managers · as of 2026-03-310,02 %$151M
- Investment Managers · as of 2026-03-310,02 %$366M
- Investment Managers · as of 2026-03-310,02 %$139M
- Institutional Investor · as of 2026-03-310,02 %$313M
- Investment Managers · as of 2026-03-310,02 %$0M
- Investment Managers · as of 2026-03-310,01 %$69M
- Investment Managers · as of 2026-03-310,01 %$62M
- Investment Managers · as of 2026-03-310,01 %$21M
- Investment Managers · as of 2026-03-310,01 %$24M
- Brokerage Firms · as of 2026-03-310,01 %$21M
- Investment Managers · as of 2026-03-310,00 %$7M
- Brokerage Firms · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 2 sellsnet -$1,1M15 insiders · last 365d
- SVP, Proprietary Segment · Common StockOther 135 @ $312,07$42K · 2026-05-12
- SVP, Proprietary Segment · Common StockOther 84 @ $312,07$26K · 2026-05-12
- SVP, Proprietary Segment · Common StockOther 296 · 2026-05-12
- SVP, Proprietary Segment · Common StockOther 474 · 2026-05-12
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Director · Common StockOther 791 · 2026-05-04
- Sr. VP & Chief HR Officer · Common StockSold 2 817 @ $305,20$860K · 2026-04-27
- VP, Chief Accounting Officer · Common StockOther 896 @ $173,22$155K · 2026-04-27
- VP, Chief Accounting Officer · Common StockSold 896 @ $300,67$269K · 2026-04-27
- Sr. VP & Chief HR Officer · Common StockOther 2 817 @ $83,47$235K · 2026-04-27
- VP & Treasurer · Common StockOther 22 @ $241,12$5K · 2026-02-20
- VP, Chief Accounting Officer · Common StockOther 30 @ $241,12$7K · 2026-02-20
- VP, Chief Accounting Officer · Common StockOther 89 · 2026-02-20
- SVP, Strategy & Corporate Dev · Common StockOther 383 · 2026-02-20
- SVP, Strategy & Corporate Dev · Common StockOther 130 @ $241,12$31K · 2026-02-20
- VP & Treasurer · Common StockOther 60 · 2026-02-20
- SVP, Strategy & Corporate Dev · Common StockOther 28 @ $248,26$7K · 2026-02-18
Short positioning
2.4Mshares short+1.9% vs prior
3.58days to cover
55.6%short of daily vol
1fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Index membership
S&P 500United States
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
WSTCanonical
NYSE · USD
Intel & risk
What changed
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
- Company share pct— → —medium
vs prior analysis 5 days ago
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 18.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 15.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 1.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 17.2%Derived (calculated)
- Return on assets (FY 2025-12-31): 11.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.02xDerived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 4.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 63.3%Derived (calculated)
- Net margin (FY 2025-12-31): 16.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 15.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 2.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -24.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.34xDerived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 0.2%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 10.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 7.5%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 6.3%Derived (calculated)
- Gross margin (FY 2025-12-31): 35.9%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
- Operating income (annual): USD 584.9MSEC XBRL filing
- Cost of revenue (annual): USD 1.97BSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 7SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-24 04:31 UTCFILINGMaterial 8-K
2026-07-23 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-03 03:12 UTCHOLDERInstitutional holding changed
2026-07-03 03:12 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-30 03:14 UTCHOLDERInstitutional holding changed
2026-06-30 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-30INSIDERHAUGEN JANET BRUTSCHEA acquired 46 sh Phantom Stock Unit — Director
2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-26 03:13 UTCHOLDERInstitutional holding changed
2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-25 03:10 UTCHOLDERInstitutional holding changed
2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-24 03:12 UTCHOLDERInstitutional holding changed
2026-06-24 03:12 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-23 03:11 UTCHOLDERInstitutional holding changed
2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
2026-05-12 00:00 UTCINSIDER16 insider transactions — 2026-05 2 derivative
2026-05-12 00:00 UTCINSIDER16 insider transactions — 2026-05 2 derivative
2026-05-12INSIDERCampbell Shane Alden transacted 135 sh — SVP, Proprietary Segment ~$42k
2026-05-12INSIDERCampbell Shane Alden transacted 84 sh — SVP, Proprietary Segment ~$26k
2026-05-12INSIDERCampbell Shane Alden transacted 296 sh — SVP, Proprietary Segment
2026-05-12INSIDERCampbell Shane Alden transacted 474 sh — SVP, Proprietary Segment
2026-05-12INSIDERCampbell Shane Alden disposed of 474 sh Rst. Stock Unit — SVP, Proprietary Segment
2026-05-12INSIDERCampbell Shane Alden disposed of 296 sh Rst. Stock Unit — SVP, Proprietary Segment
2026-05-04INSIDERJoseph Molly transacted 791 sh — Director
2026-05-04INSIDERPucci Paolo transacted 791 sh — Director
2026-05-04INSIDERMichels Douglas A transacted 791 sh — Director
Showing the 40 most recent of 97 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage